Arbutus Biopharma (LTS:0SGC) Debt-to-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Arbutus Biopharma Debt-to-Asset?

Arbutus Biopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.48 Mil. Arbutus Biopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.81 Mil. Arbutus Biopharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $131.71 Mil. Arbutus Biopharma's debt to asset for the quarter that ended in Dec. 2024 was 0.01.

Arbutus Biopharma Debt-to-Asset Historical Data

The historical data trend for Arbutus Biopharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arbutus Biopharma Debt-to-Asset Chart

Arbutus Biopharma Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.02

0.01

Arbutus Biopharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Competitive Comparison of Arbutus Biopharma's Debt-to-Asset

For the Biotechnology subindustry, Arbutus Biopharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arbutus Biopharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Arbutus Biopharma's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Arbutus Biopharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Arbutus Biopharma's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.483	+	0.806)	/	131.707
	=	0.01

Arbutus Biopharma's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.483	+	0.806)	/	131.707
	=	0.01

Arbutus Biopharma (LTS:0SGC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Arbutus Biopharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Arbutus Biopharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Arbutus Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arbutus Biopharma Corp (LTS:0SGC) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ABUS:USA I9DN:Germany I9DN:Germany

Address

701 Veterans Circle, Warminster, PA, USA, 18974

Website

http://www.arbutusbio.com

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Arbutus Biopharma Headlines

No Headlines